UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   Washington, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

 Pursuant to Section 13 or 15(d) of the Securities Exchange
                         Act of 1934



Date of Report:           April 11, 2005
                (Date of earliest event reported)



                    Allen Organ Company
   (Exact name of registrant as specified in its charter)


    Pennsylvania                 0-275                    23-1263194
(State or other jurisdiction   (Commission              (IRS Employer
  of incorporation)            File Number)           Identification No.)



150 Locust Street, P.O. Box 36, Macungie, Pennsylvania   18062-0036
(Address of principal executive offices)                 (Zip Code)



                              610-966-2200
          (Registrants telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the
      Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the
      Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-
      2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-
      4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01 Notice of Delisting or Failure to Satisfy a
          Continued Listing Rule or Standard; Transfer of
          Listing

The Board of Directors of Allen Organ Company authorized and
directed management of the Company to prepare and file with
the Securities and Exchange Commission on or about May 12,
2005, a Form 15 relating to its Class B common stock to
deregister the Class B common stock under the Securities
Exchange Act of 1934.  As a result of such action, the Class
B common stock will no longer be eligible for listing on the
NASDAQ stock market.  Accordingly, in connection with
deregistration of the Class B common stock under the
Securities Exchange Act of 1934, the Company will also
terminate the listing of the Class B common stock on NASDAQ
on or about May 12, 2005.  A copy of the press release is
attached as Exhibit 99.1 and is incorporated herein by
reference.

Item 8.01 Other Events

On April 11, 2005, Allen Organ Company issued a press
release announcing its intention to file a Form 15 relating
to its Class B common stock with the Securities and Exchange
Commission on or about May 12, 2005 to deregister these
securities and suspend the Company's reporting obligations
under the Securities Exchange Act of 1934.  Upon filing the
Form 15, the Company's securities will no longer be eligible
for quotation on NASDAQ and instead will be eligible for
quotation on the pink sheets.  A copy of the Press Release
is attached as Exhibit 99.1 and is incorporated herein by
reference.


Item 9.01 Financial Statements and Exhibits

(c)       Exhibits
          99.1 - Press Release dated April 11, 2005,
          announcing Allen Organ Company's plans to
          deregister its Class B common stock under the
          Securities Exchange Act of 1934.




                         Signatures

Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.

                                     ALLEN ORGAN COMPANY

Date:      April 11, 2005          /s/ STEVEN MARKOWITZ
                                   Steven Markowitz, President